Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and99mTc-MDP bone scan in progressing metastatic prostate cancer

Clinical Cancer Research

Volumn 16, Issue 24, 2010, Pages 6093-6099

  Meirelles, Gustavo S P ^a   Schöder, Heiko ^a   Ravizzini, Gregory C ^a   Gönen, Mithat ^a   Fox, Josef J ^a   Humm, John ^a   Morris, Michael J ^a   Scher, Howard I ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BONE LESION; BONE SCINTISCANNING; CANCER GROWTH; CANCER SURVIVAL; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; CARCINOMA; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TECHNETIUM TC 99M MEDRONATE;

EID: 78650339897     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1357     Document Type: Article

References (24)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
2. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
3. Yamashita K, Denno K, Ueda T, et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993;71:1297-302.
4. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 1998;4:1765-72.
5. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17:948-57.
6. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8.
7. Obuchowski NA. On the comparison of correlated proportions for clustered data. Stat Med 1998;17:1495-507.
8. Costelloe CM, Macapinlac HA, Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 2009;50:340-7.
9. de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol 2006;17:1650-5.
10. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose- positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-60.
11. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-54.
12. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 2006;47:1260-6.
13. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose- positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
14. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of nonsmall- cell lung cancer. J Clin Oncol 2005;23:1136-43.
15. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-51.
16. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60.
17. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6.
18. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-208.
19. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008; 247:189-96.
20. Specht JM, Tam SL, Kurland BF, et al. Serial 2-[18F] fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007;105:87-94.
21. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996;23:693-7.
22. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
23. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-92.
24. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11:3210-6.